Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma

European Urology- Netherlands

doi 10.1016/j.eururo.2015.12.025

Full Text

Abstract

Available in

Categories

Urology

Date

Authors

Publisher

Elsevier BV

Related search

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice
Oncology
2019English

Outcomes Based on Age in the Phase III METEOR Trial of Cabozantinib Versus Everolimus in Patients With Advanced Renal Cell Carcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

Clinical Experience and Critical Evaluation of the Role of Everolimus in Advanced Renal Cell Carcinoma

Research and Reports in Urology
Urology
2011English

Nivolumab in Treatment of Renal Cell Carcinoma During Renal Replacement Therapy

Oncology in Clinical Practice
Oncology
2019English

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab

Clinical Genitourinary Cancer
OncologyUrology
2017English

Axitinib, Cabozantinib, Everolimus, Nivolumab, Sunitinib and Best Supportive Care in Previously Treated Renal Cell Carcinoma: A Systematic Review and Economic Evaluation

Health Technology Assessment
MedicineHealth Policy
2018English

Complete Remission of Bone Metastases in Renal Cell Carcinoma With Nivolumab

Cureus
2019English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy